#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Leukocyte adhesion deficiency type I Hydrocephalus Colorectal adenocarcinoma Oesophageal squamous cell carcinoma Cystic fibrosis lung Cardiac arrest Brain stem glioma Pericarditis Myotonia Epstein-Barr virus infection Hepatoblastoma Pulmonary arterial hypertension Non-Hodgkin's lymphoma unspecified histology indolent Palmoplantar pustulosis Haemophilia B without inhibitors More trials…

    Learn about Rare Diseases

    Lymphangiosarcoma – Basic Information Usher’s syndrome – Life with Disease Gaucher’s disease type III – Basic Information Crigler-Najjar syndrome – Trials in Disease Nephroblastoma – Treatment Hyperoxaluria – Diagnostics Mucopolysaccharidosis II – Life with Disease Osteosarcoma recurrent – Trials in Disease Breast angiosarcoma – Basic Information Marfan’s syndrome More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Opevesostat Tosilate Mebeverine Hydrochloride AZD0516 Oxacillin Tipiracil Hydrochloride Pralsetinib Bdc-1001 Vepdegestrant ANERATRIGINE MESILATE Arrhenatherum Elatius Regn7075 Human Albumin Solution Pirtobrutinib Losartan Potassium Alectinib RLY-2608 Estriol AVTX-009 Semaglutide DUVELISIB More therapies…

    Learn about Your Condition

    Choreoathetosis Anal fistula Complicated appendicitis Metastases to liver Gout Pleomorphic leiomyosarcoma Neuroendocrine tumour Osteopenia Osteomyelitis acute Immune system disorder B-cell lymphoma Incisional hernia Myelofibrosis Anxiety Septic shock More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello…

Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello

Via Trabucco 180, Palermo, 90146, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Venetoclax and Dexamethasone with Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Betamethasone Sodium Phosphate Ph. Eur
    • Pomalidomide
    • Venetoclax
    Czechia Denmark France Germany Greece Italy +1

  • Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Lenalidomide
    • Rituximab
    • Tafasitamab
    Austria Belgium Czechia Denmark Finland France +10

  • Study of Zilovertamab Vedotin with Drug Combination for Patients with Diffuse Large B-Cell Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Zilovertamab Vedotin
    • Betamethasone Sodium Phosphate
    • Cyclophosphamide
    Italy Poland Spain

  • Study on the Effects of Eclitasertib in Adults with Moderate to Severe Ulcerative Colitis

    Not recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Eclitasertib
    Bulgaria Czechia France Germany Hungary Italy +5

  • Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Obefazimod
    Austria Belgium Bulgaria Czechia France Germany +7

  • Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn’s Disease After Anti-TNF Therapy Failure

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Risankizumab
    • Ustekinumab
    Austria Belgium Bulgaria Czechia France Germany +8

  • Study comparing tarlatamab with topotecan in patients with relapsed small cell lung cancer after first-line chemotherapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Ammonium Chloride
    • Siltuximab
    • Tarlatamab
    Austria Belgium Czechia Denmark France Germany +9

  • Study on Tulisokibart for Treating Moderate to Severe Crohn’s Disease in Adults

    Not recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Tulisokibart
    Austria Belgium Croatia Czechia Denmark Finland +15

  • Study of Romidepsin and Drug Combination for Young Patients with Peripheral T-Cell Lymphomas Before Stem Cell Transplantation

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Angioimmunoblastic T-cell lymphoma
    • Peripheral T-cell lymphoma unspecified
    • Anaplastic large cell lymphoma T- and null-cell types
    Investigated Drugs:
    • Romidepsin
    Italy

  • Study of Acalabrutinib Alone or with Rituximab for Patients with Relapsed/Refractory Marginal Zone Lymphoma

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • B-cell lymphoma
    Investigated Drugs:
    • Acalabrutinib
    Italy
Previous Page
1 … 8 9 10 11
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!